Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
There is mention of utilizing funds for follow on investments so it's entirely possible. I still wonder whether the BoD will throw a load of cash into AZD1656 for phase three trials (as a standalone covid treatment) once it has been commercialized to treat diabetic patients.
I'm not really sure what the board are playing at. No such thing as a consolidation that improves the real life value to shareholders. Hopefully SGS pull their finger out ahead of the AGM so the team at VELA have something positive to talk about.
VELA receives 8% of the proceeds of the sale/licensing of AZD1656 (Excluding the first £19.2 million)
Original RNS: https://www.lse.co.uk/rns/VELA/investment-in-potential-covid-treatment-placing-7d8tgl50wf3qrkm.html
In the event that AZD is sold for £100m
- £19.2m = £80.8m
8% of £80.8m = £6.464m due to VELA
Many investors are expecting the sale/licensing deal will be worth significantly more (Potentially over £200m)
In short, the right deal could double/triple/quadruple the value of the company.
Its all retail buyers/traders dealing in small amounts so the SP isn't going to do much. There was some decent size buying/accumulation last week. Those that believe AZD1656 is a success will no doubt have already taken their positions ahead of news.
Annoyingly I think the limited information shared about the trial success has a lot to do with AstraZeneca wanting to keep a lid on everything until contracts are signed. This really doesn't help investors in the short term but it certainly will come the big day when an RNS lands (hopefully very soon).
Hold for Gold
I don't think it would be considered a closed period as the companies and their directors are not considered insiders given everything is being handled by SGS (VELS/Mush et al are simply investors like you and I). Commercialisation news could be dropped by SGS at any time so I guess some directors are buying off the back of this weeks RNS confident that everyone is in for a pay day..
Anything under the 0.8-0.9 range is cheap. As mentioned on here yesterday the value of VELA is still at a level that suggests the SGS outcome is unknown despite the fact that is looks like a nailed on success.
Well done to those loading up at this level as it will look like a complete bargain in less than a handful of weeks.
I am slightly surprised we didn't see a 50%+ rise yesterday. Perhaps we will see a more gradual rise as the dust settles and the media start promoting the success of the trials.
That's right, a company with an 8% share in a covid beating tablet that could save thousands of lives is currently valued at £9m.
Talk about an investment opportunity. Mega entry point for new investors (And yes I am incredibly jealous of those picking up shares at bargain basement levels as my average is significantly higher )
Sub 0.8 we are essentially valued on the basis that the SGS trial outcome is unknown.
We know AZD1656 is both safe and effective in treating covid patients with diabetes and commercial talks are underway. I wouldn't be surprised to see the SP head back to the 0.8 - 0.9 range on todays RNS as it basically indicates that everything is going according to plan. We just need commercialisation news and potentially an indication of further trials as a standalone covid treatment that could be worth a huge sum of money.
I am intrigued?! VELA managed to acquire 8% with an investment of £2.5m (ish).
On that valuation a controlling stake @ 51% would come in at circa £15,937,500. I'm pretty sure that this amount would be too low given the progression made since the first investment (AZD1656 is worth a lot more given completion of phase 2 trials) and more to the point where have the bod managed to get another £13.5m from :)
I don't suppose you can offer up any more information regarding this email?
The phrase "the silence is far from deliberate" may suggest to some that someone/somewhere is dragging their feet? (resulting in VELA being unable to offer up any information)
Either way, its nice to hear the Brent has responded to an email.
Come on VELA, give us the SGS news and put the SP back to where it belongs!
Baffling to see selling continue at this level (no one is making anything). Although I agree that the news flow has been limited, there appears to be a complete lack of patience from holders who are not willing to wait more than a month or two.
Does anyone subscribe to the idea that we will only get news on SGS/Arcadia once Igraine are back to trading? If so, what sort of timescales are we looking at as Igraine should have been back to business as normal over a month ago (accounts still overdue)
I'm sorry but I am calling bull s**t on that gmail account. VELA have their own web domain so have no reason to be using a third party email provider.
The email address they have published is: info@velatechplc.com but I haven't had a response from anyone to don't know who is reviewing what is landing on the doormat.
Its official - we are -50% vs the closing price on the 8th September 2021. The board must be over the moon with what they have achieved!
Does anyone have any contact information for the Board or SGS?. I have tried the details on the website and had no response.
As much as I trust my initial investment decision and have built up a considerable holding (having averaged down quite a bit), the lack of info on the arcadia trials and the £2m sat in the bank is starting to irritate me a little.
He must know something!
The board are surely not going to sit on their hands and watch the share price continue to fall.
Plenty of news in the pipeline. It just seems to be taking an age to get the meaningful stuff into the public domain.